TCT 2025 - Long-term follow-up of the PARTNER 3 trial showed no safety concerns for transcatheter aortic-valve replacement (TAVR) compared to surgical treatment of aortic stenosis (AS).

Dr Michael Mack (Baylor Scott & White Heart Hospital, Plano, US) joins us to share the clinical and echocardiographic outcomes from the seven-year follow-up of the PARTNER 3 low-risk randomised trial (NCT02675114). The follow-up investigated clinical and echocardiographic outcomes in patients with severe, symptomatic AS and low surgical risk who were randomised to undergo either TAVR or surgery.

Findings showed identical results of the primary composite endpoint of death, stroke and rehospitalisation for TAVR compared to surgical treatment at seven years. The second primary composite endpoint showed surgery decreased rates of death and disabling stroke compared to TAVR; however, TAVR decreased rates of non-disabling stroke and rehospitalisation.

Interview Questions:
1. What was the rationale behind this study?
2. What was the study design and patient population of the follow-up?
3. What were the key clinical and echocardiographic findings?
4. How should these findings impact clinical practice?
5. What further research is needed in this area?
6. Could you tell us about what you found when looking at the recent data on higher reintervention rates with TAVI verses surgery?

Recorded on-site at TCT Conference in San Francisco, 2025.
Editor: Yazmin Sadik
Video Specialist: Dan Brent.

Support: This is an independent interview produced by Transcatheter Academy.